Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Retained Earnings: 2009-2025

Historic Retained Earnings for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Sep 2025 value amounting to -$2.0 billion.

  • Madrigal Pharmaceuticals' Retained Earnings fell 16.59% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 16.59%. This contributed to the annual value of -$1.8 billion for FY2024, which is 34.86% down from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Retained Earnings stood at -$2.0 billion for Q3 2025, which was down 5.95% from -$1.9 billion recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Retained Earnings ranged from a high of -$478.0 million in Q1 2021 and a low of -$2.0 billion during Q3 2025.
  • Its 3-year average for Retained Earnings is -$1.6 billion, with a median of -$1.6 billion in 2024.
  • Data for Madrigal Pharmaceuticals' Retained Earnings shows a maximum YoY slumped of 84.28% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Madrigal Pharmaceuticals' Retained Earnings stood at -$667.3 million in 2021, then crashed by 44.27% to -$962.7 million in 2022, then plummeted by 38.81% to -$1.3 billion in 2023, then slumped by 34.86% to -$1.8 billion in 2024, then fell by 16.59% to -$2.0 billion in 2025.
  • Its last three reported values are -$2.0 billion in Q3 2025, -$1.9 billion for Q2 2025, and -$1.9 billion during Q1 2025.